Company intelligence / Profile preview

Lynntech

College Station, Texas, United States

Ownership: Private
Employees: ~107
Development stage: Other

Overview

Lynntech has several early-stage health technology programs, including preclinical and prototype-stage devices for infectious disease diagnostics, wound healing, and health-related data analysis. Selected programs have entered animal model studies and SBIR Phase I/II development, with a cutaneous gel for diabetic foot ulcers and next-gen HIV bNAb delivery being recent highlights[2].

Therapeutic areas: DermatologyOtherInfectious DiseasesEndocrinology
Modalities: DeviceSmall moleculeBiologicAntibodyRNA therapySoftware
Industry: Biotech

Partnerships

Texas Tech University Health Science Center[2]University of Miami Miller School of Medicine[2]Centers for Disease Control and Prevention (CDC)[2]Texas A&M University[2]

Beyond the preview

Go deeper on Lynntech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lynntech.

Explore the full profile